| Next 10 |
Ad
SILO Articles Silo Pharma Inc.
home / stock / silo / silo articles
Articles | Silo Pharma Inc. (NASDAQ:SILO)
-
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow traded down 0.91% to ...
-
Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insur...
-
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points on Friday. The Dow traded down 0.78% to 40,3...
-
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% t...
-
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The...
-
Silo Pharma Inc (NASDAQ:SILO) stock is surging on Thursday, with a session volume of 88 million compared to an average volume of 3.2 million, as pe...
-
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 200 points on Thursday. The Dow traded down 0.61% to 4...
-
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 40 points on Thursday. Following the market opening Thursday, the D...
-
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership wi...
Stock Information
Get SILO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Silo Pharma (NASDAQ: SILO) has entered into a collaboration with Kymanox to develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant designed to treat fibromyalgia and chronic pain. The partnership will begin with proof-of-concept design, followed by prototype and feasibili...
-
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on dev...
-
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE...